Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 5/20 | 0.68 |
| ▸ | POLB | P06746 | 3/20 | 0.68 |
| ▸ | THRB | P10828 | 2/20 | 0.67 |
| ▸ | TP53 | P04637 | 2/20 | 0.62 |
| ▸ | NR1H4 | Q96RI1 | 3/20 | 0.46 |
| ▸ | NPC1 | O15118 | 3/20 | 0.45 |
| ▸ | RAB9A | P51151 | 3/20 | 0.45 |
| ▸ | LMNA | P02545 | 2/20 | 0.45 |
| ▸ | MAOA | P21397 | 1/20 | 0.45 |
| ▸ | MAOB | P27338 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2171108 | 0.88 | MAPT (0.79) | MAPTPOLBTHRBTP53NR1H4 | |
| SCHEMBL2547296 | 0.87 | MAPT (0.69) | MAPTPOLBTHRBTP53NR1H4 | |
| SCHEMBL2171100 | 0.87 | MAPT (0.69) | MAPTPOLBTHRBTP53NPC1 | |
| SCHEMBL2547306 | 0.86 | MAPT (0.79) | MAPTPOLBTHRBTP53NR1H4 | |
| SCHEMBL2186610 | 0.83 | MAPT (0.72) | MAPTPOLBTP53NPC1RAB9A | |
| SCHEMBL2173304 | 0.82 | POLB (0.68) | MAPTPOLBTHRBTP53NR1H4 | |
| SCHEMBL2172878 | 0.82 | TP53 (0.68) | MAPTPOLBTHRBTP53NR1H4 | |
| SCHEMBL2173312 | 0.82 | MAPT (0.61) | MAPTPOLBTHRBTP53NR1H4 | |
| SCHEMBL2542223 | 0.81 | MAPT (0.66) | MAPTPOLBTP53 | |
| SCHEMBL2546279 | 0.80 | MAPT (0.55) | MAPTPOLBTHRBTP53NR1H4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110263588-A1 | TRICYCLIC COMPOUNDS AS GLUTAMATE RECEPTOR MODULATORS | GLAXO GROUP LIMITED (GB) | 2011-10-27 | — | — | US | claimed |
| US-20110263588-A1 | TRICYCLIC COMPOUNDS AS GLUTAMATE RECEPTOR MODULATORS | GLAXO GROUP LIMITED (GB) | 2011-10-27 | — | — | US | disclosed |
| EP-2346832-A1 | TRICYCLIC COMPOUNDS AS GLUTAMATE RECEPTOR MODULATORS | Glaxo Group Limited (GB) | 2011-07-27 | — | — | EP | disclosed |
| WO-2010049366-A1 | TRICYCLIC COMPOUNDS AS GLUTAMATE RECEPTOR MODULATORS | GLAXO GROUP LIMITED (GB) | 2010-05-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110263588-A1 | TRICYCLIC COMPOUNDS AS GLUTAMATE RECEPTOR MODULATORS | GRM5, GRM1, GRM3 | MAPT 2044/4885POLB 4360/4885THRB 244/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.